Lipum AB: BioStock: Lipum approaches the finish line in the study - last patient recruited
Lipum has recruited all rheumatoid arthritis patients for the final stage of its phase I study with SOL-116. With a 90-day follow-up period remaining, the study is on track for completion around the end of the year. CEO Ola Sandborgh discusses this milestone in an interview.
Read the full article at biostock.se (https://www.biostock.se/en/):
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se